Introduction {#Sec1}
============

Pneumonia contributes significantly to global childhood morbidity and mortality. The World Health Organization (WHO) estimates that there are 156 million cases of pneumonia each year in children younger than 5 years, with as many as 20 million cases severe enough to require hospital admission \[[@CR1]\].

Atypical pneumonia is used to describe pneumonia caused by atypical pathogens such as *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, *Legionella pneumophili*, and others. The clinical course among children infected with these pathogens is different from that of other bacterial or viral infection, most of them progress slowly and have no specific symptoms. Many studies reported that *Mycoplasma pneumoniae* is the most common atypical pathogen found among children with community-acquired pneumonia (CAP), followed by *Chlamydia pneumoniae* \[[@CR2]--[@CR4]\].

Pertussis (whooping cough) is a respiratory tract infection caused by the Gram-negative bacterium *Bordetella pertussis*. Pertussis is a highly infectious disease and can cause significant morbidity in infants. Recent evidence shows an appreciable incidence of pertussis among infants presenting with acute pneumonia. In a birth cohort, 2% of clinical pneumonia cases among enrolled infants were caused by pertussis \[[@CR5]\]. Another study reported that 3.7% of infants and young children presenting to a tertiary academic hospital had evidence of pertussis infection \[[@CR6]\]. Most deaths from pertussis occur in developing countries and among children during the first months of life \[[@CR7]\]. The WHO estimated that in 2013, *Bordetella pertussis* caused approximately 60,257 deaths in children \< 5 years of age \[[@CR8]\].

*Mycoplasma pneumoniae* infection shows a variety of clinical manifestations, ranging from asymptomatic infection to fatal pneumonia and may be associated with neurological and systemic symptoms (e.g., rashes). *Mycoplasma pneumoniae* pneumonia has been reported in 10 to 40% of CAP cases, and children are the most susceptible group to mycoplasma infection \[[@CR9]\].

The importance of the atypical pathogens as causative agents of pneumonias is not related to their frequency, but to their difficulty of diagnosis and their non-responsiveness to beta-lactam therapy \[[@CR10]\]. Atypical bacteria require specific antibiotic coverage because conventional antibiotics used against typical organisms such as streptococci are not effective. Increasing rates of identification of atypical pathogens as a cause of CAP have been reflected in treatment guidelines favoring antibiotics with atypical coverage for certain patients hospitalized with severe CAP \[[@CR11]\].

Investigations of typical pathogens causing CAP in children do not include atypical pathogens because it is difficult to detect them by culture methods \[[@CR2]\]. On the other hand, multiplex PCR methods enable testing for several pathogens simultaneously in a single analysis.

So, the aim of this study was to determine the role of *Bordetella pertussis*, *Mycoplasma pneumoniae*, *Chlamydia pneumonia*, and *Legionella pneumophilia* in community-acquired pneumonia in children using the real-time PCR as the principal method for determination and also to study the relation, if any, between the presence of these pathogens and clinical, laboratory, and radiological variables.

Materials and methods {#Sec2}
=====================

Study design and subjects {#Sec3}
-------------------------

This cross-sectional study was conducted throughout a 2-year period from 1 September 2015 to 31 August 2017. All children fulfilling criteria of case definition of CAP who were hospitalized during this period were enrolled. The study included 400 eligible children, and they were recruited from Emergency Departments of Cairo University Children's hospitals (The specialized Children Hospital and El Monira Children Hospital), tertiary hospitals that receive patients from all over Egypt. Inclusion criteria were previously healthy children hospitalized with a clinical diagnosis of CAP and patient's age range from 2 months to 12 years. Exclusion criteria were patients with underlying chronic lung disease, congenital heart disease, immunodeficiency, and chronic hepatic or renal diseases.

Methods {#Sec4}
=======

Data was collected by full-history taking and meticulous clinical examination of all the studied population. All cases were diagnosed to have pneumonia according to WHO case definition of pneumonia \[cough or difficult breathing and respiratory rate more than WHO range for age (respiratory rate ≥ 60 breaths/min for children \< 2 months; ≥ 50 breaths/min for children 2--11 months; ≥ 40 breaths/min for children 12--59 months)\] \[[@CR12]\].

CAP is defined as pneumonia that has been acquired in the community in a patient who has not been hospitalized within 14 days prior to the onset of symptoms or has been hospitalized less than 4 days prior to the onset of symptoms \[[@CR11]\]. Criteria for classification as severe pneumonia in children include the following: lethargy, unconsciousness, convulsions, inability to drink, vomiting, and lower chest wall indrawing \[[@CR13]\].

Clinical specimens {#Sec5}
------------------

Complete blood count (CBC) was determined at the time of study enrollment for each patient. Sputum samples (2 ml) were collected from the lower respiratory tract of all enrolled patients by using mucus trap catheter after sputum induction. The samples were transported to the laboratory in an ice container and stored at − 70 °C.

Molecular identification by real-time PCR {#Sec6}
-----------------------------------------

Molecular detection of *Bordetella pertussis*, *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, and *Legionella pneumophilia* was done by multiplex real-time PCR using AnyplexTM II RB5 Kit (Cat. No. RB7500Y, Seegene, Korea), operated on Biorad CFX 96 real time machine, according to the manufacturer's instructions \[[@CR14]--[@CR16]\].

Pre-treatment of specimen was done by adding saline solution with the specimen (1:2), vortexed for 1 min, then incubated for 20 min at room temperature.

Conditions and cycles of RT PCR were as follows:SegmentNo. of cyclesTemperatureDuration1150 °C4 min2195 °C15 min33095 °C30 s460 °C1 min572 °C30 s6155 °C30 s71Melting curve 55 \~ 85 °C (5 s/0.5 °C)81095 °C30 s960 °C1 min1072 °C30 s11155 °C30 s121Melting curve 55 \~ 85 °C (5 s/0.5 °C)131095 °C30 s1460 °C1 min1572 °C30 s16155 °C30 s171Melting curve 55 \~ 85 °C (5 s/0.5 °C)

RB5 PC-positive control included in the kit was used in each run. It contains mixture of pathogen clones. Also, internal control was added to each sample from the start to ensure high-quality amplification occurred for every sample. The RB5 internal control (IC) controlled not only the nucleic acid isolation procedure but also the possibility of PCR inhibition. Ten microliters of the RB5 IC was added to each specimen before the nucleic acid extraction. Nucleic acid isolation was done using Ribo_spinvRD kit (Cat. No302-150SG1701) from GeneAll.

Statistical analysis {#Sec7}
--------------------

Data was subjected to computer-assisted statistical analysis using statistical package for social science program IBM SPSS (Statistical Package for the Social Science; IBM Corp, Armonk, NY, USA) release 22 for Microsoft Windows. Nominal data was expressed as frequency and percentage and was compared using chi-square test. Numerical data was expressed as mean ± standard deviation and was compared using *T* test. Non-parametric data was expressed as median "interquartile range" and was compared using Mann-Whitney *U* test. Associations between numerical variables were studied using Pearson's correlation. *P* values less than 0.05 were considered significant.

Ethical considerations {#Sec8}
----------------------

This study was approved by Cairo University Clinical Research Ethics Committee, and informed verbal consents were obtained from parents of the included children. The study design conformed to the Revised Helsinki Declaration of Bioethics.

Results {#Sec9}
=======

Among the 400 CAP cases enrolled in this study, atypical pathogens were detected by multiplex PCR in 12/400 (3%) patients. Their mean age was 13.75 ± 15.46 months. Sixty percent of patients were males and 40% were females. A large proportion of the patients had severe pneumonia 104/400 (26%), of them 44 (11%) needed pediatric intensive care unit (PICU) admission. The detailed demographic and clinical characteristics of patients are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Demographic and clinical characteristics of children with community-acquired pneumonia, Cairo University Specialized Pediatric HospitalCharacteristics*N* (%)Age in months (range)2--84Mean ± SD13.75 ± 15.46Age groups ≤ 4 months104 (26%) \> 4 months ≤ 59 months272 (68%) \> 59 months24 (6%)Sex Male240 (60%) Female160 (40%)Incomplete vaccination200 (50%)Fever384 (96%)Prolonged cough \> 14 days20 (5%)Chest indrawing324 (81%)Rhonchi76 (19%)Grunting64 (16%)Cyanosis52 (13%)Refusal of feeding104 (26%)Vomiting108 (27%)Lethargy44 (11%)Convulsion24 (6%)Severe pneumonia104 (26%)ICU admission44 (11%)Radiological findings Unilateral affection176 (44%) Bilateral affection224 (56%) Number of involved lobes  One lobe88 (22%)  Two lobes or more312 (78%) Alveolar consolidation388 (97%) Consolidation collapse40 (10%) Interstitial infiltration140 (35%) Pleural effusion32 (8%)Total leukocytic count Mean ± SD10.77 ± 5.37 Leukocytosis \> 15,00088 (22%) Lymphocytosis80 (20%) Neutropenia8 (2%)Data are described in number of cases (%) and mean ± SD

*Bordetella pertussis* was responsible for CAP in 8/400 (2%) patients, and *Mycoplasma pneumoniae* was determined as the cause of CAP in 4/400 (1%) patients in this study. None were positive for either *C. pneumoniae* or *Legionella pneumophilia* by PCR, as are shown in Table [2](#Tab2){ref-type="table"}.Table 2The frequency of pathogen detection using the multiplex PCR among the CAP patientsOrganismNumber (%)*Bordetella pertussis*8 (2%)*Mycoplasma pneumoniae*4 (1%)*Chlamydia pneumoniae*0 (0%)*Legionella pneumophilia*0 (0%)Data are described in number of cases (%)*CAP* community-acquired pneumonia

In this work, we did not encounter co-infection by more than one pathogen.

On studying the frequency of pathogen detection among different age stratums, *Bordetella pertussis* was detected in 8/104 (7.69%) infants ≤ 4 months, and pertussis-positive cases were significantly less than 4 months (*P* value ≤ 0.001). All cases of CAP caused by *Mycoplasma pneumonia* were among the age stratum \> 4 months ≤ 59 months, as are shown in Table [3](#Tab3){ref-type="table"}.Table 3Correlating the frequency of pathogen detection to different age groupsPathogenAge groups (months)≤ 4 months\> 4 months ≤ 59 months\> 59 months*P* value*n* = 104*n* = 272*n* = 24*Bordetella pertussis*8 (7.79%)0 (0%)0 (0%)≤ 0.001*Mycoplasma pneumoniae*0 (0%)4 (1.47%)0 (0%)0.3*P* values \> 0.05 is statistically insignificant

Severe pneumonia was recorded in 50% of pertussis-positive patients with no need for PICU admission. Mycoplasma-positive cases did not record severe pneumonia or PICU admission.

On comparing clinical and radiological characteristics of pertussis-positive versus pertussis-negative cases in this study, the percentages of associated upper respiratory symptoms, vomiting, prolonged cough \> 14 days, and interstitial infiltration were significantly related to pertussis-positive cases (*P* value was 0.001 for each). Mycoplasma-positive cases were more likely to have unilateral lung involvement with interstitial infiltration compared to mycoplasma-negative cases (*P* value was 0.03 and 0.01, respectively), as are demonstrated in Table [4](#Tab4){ref-type="table"}.Table 4Comparing *P* value of associated clinical, laboratory, and radiographic findings among positive versus negative pertussis and mycoplasma casesVariablesPertussis-positive versus pertussis-negative casesMycoplasma-positive versus mycoplasma-negative casesProlonged cough \> 14 days≤ 0.001\*\> 0.999Upper respiratory symptoms0.001\*0.13Chest indrawing0.04\*\> 0.999Rhonchi0.04\*\> 0.999Grunting0.36\> 0.999Cyanosis0.6\> 0.999Refusal of feeding0.110.57Vomiting0.001\*0.57Lethargy0.61\> 0.999Convulsion1.0\> 0.999Severe pneumonia0.10.5ICU admission0.6\> 0.999Incomplete vaccination0.007\*0.12Radiological findings Unilateral affection0.70.03\* Bilateral affectionNumber of involved lobes 1 lobe0.080.29 2 lobes or moreAlveolar consolidation1.0\> 0.999Interstitial infiltration0.001\*0.01\*Total leukocytic count Leukocytosis \> 15,0000.070.58 Lymphocytosis0.050.5\**P* values \< 0.05 is statistically significant

Discussion {#Sec10}
==========

This study identified atypical pathogens as a potential etiologic agents in community-acquired pneumonia in 12/400 (3%) patients by the use of multiplex PCR. *Bordetella pertussis* was detected in 2% of cases, and it was responsible for CAP in 8/104 (7.69%) infants in the age stratum ≤ 4 months; *Mycoplasma pneumoniae* was detected in 1% of enrolled cases, all were among the age stratum \> 4 months ≤ 59 months in 4/272 (1.47%) children.

Compared with pertussis-negative cases, pertussis-positive cases were younger and incompletely vaccinated against *Bordetella pertussis*, and this is in agreement with Sadiasa et al. \[[@CR17]\] who found that *Bordetella pertussis* was the most common atypical pneumonia pathogen among hospitalized children. Higher frequencies of pertussis were recorded by Lassmann et al. \[[@CR18]\] in Gabon, where they demonstrated that *Bordetella pertussis* caused 6% of cases of CAP in their study; all children who were tested positive for *B. pertussis* were not or only partially immunized. The tendency to infect young unvaccinated or incompletely vaccinated infants suggests the role for maternal pertussis immunization that can significantly increase antibody level for further reduction of disease burden during early infancy.

Pertussis-positive cases in this study were more likely to have been associated with upper respiratory symptoms, vomiting, and prolonged cough \> 14 days. Similar results were recorded by Barger-Kamate et al. \[[@CR19]\], and this is in concordance with the WHO recommended clinical case definition \[[@CR20]\].

In the current study, *Mycoplasma pneumoniae* infection was detected in 1% of cases, which is relatively low, but in keeping with previous studies that reported the detection of *Mycoplasma pneumoniae* by PCR in 1.3% and 4.5% of children aged ≤ 5 years \[[@CR21], [@CR22]\]. Higher frequencies of detection of *Mycoplasma pneumoniae* were reported by Defilippi et al. and Hadi et al. who reported 12% and 10% detection rate, respectively \[[@CR23], [@CR24]\].

The propensity of *Mycoplasma pneumoniae* detection in the age stratum \> 4 months ≤ 59 months in this study could be explained by the mean age of the study population that was 13.75 ± 15.46 months. This finding is supported by Lassmann et al. \[[@CR18]\] in Gabon who found that all children who were tested positive for atypical pathogens were less than 5 years old.

Similar to what previously reported by Agarwal et al. \[[@CR25]\], this study did not detect *Chlamydia pneumoniae* among cases with CAP. In contrast, Samransamruajkit et al. \[[@CR26]\] in Thailand found that *Chlamydia pneumoniae* was responsible for 12.5% of cases of CAP in their study. The available literature supports a low prevalence of *Chlamydia pneumoniae* infection in children younger than 5 years, but it is an important cause of pneumonia among older children \[[@CR27]\]. The rate of isolation of *Chlamydia pneumoniae* from acute lower respiratory tract infections in children ranges from 0 to 18% \[[@CR3], [@CR25], [@CR28]--[@CR30]\].

Despite that *Legionella pneumophilia* infection in hospitalized children with CAP has been reported in some studies \[[@CR2], [@CR31], [@CR32]\], we did not detect legionella infection among enrolled cases in this study, and this could be explained by our exclusion criteria where we excluded all cases with underling chronic diseases or malignancies. It has been reported that the majority of children with Legionnaires' disease have an underlying condition such as malignancy \[[@CR33]\], renal or liver failure, diabetes, and other conditions that compromise the immune system \[[@CR34]\].

There was no significant difference in clinical presentations or TLC between *Mycoplasma pneumoniae*-positive and *Mycoplasma pneumoniae*-negative cases, this is in agreement with Hadi et al. \[[@CR24]\] in Iran and Lassmann et al. \[[@CR18]\] in Gabon. Also, this was supported by Somer et al. who stated that a clinical diagnosis of infection by atypical bacteria remains elusive \[[@CR28]\]. Chest X-ray of mycoplasma-positive cases showed a significant unilateral interstitial infiltration; this is in agreement with other studies \[[@CR24], [@CR27]\].

The present study recorded severe pneumonia in 26% of enrolled cases and PICU admission in 11% of cases. Severe pneumonia was encountered in 50% of pertussis-positive patients without the need for PICU admission. At the same time, mycoplasma-positive cases were not associated with severe pneumonia or PICU admission. These findings could be explained by the significantly younger age of pertussis-positive cases. This is consistent with Le Huong et al. \[[@CR2]\] in Vietnam, where they found that the highest proportion of severe CAP infections occurred in children younger than 2 years, so the younger the child, the more likely that the atypical pathogen CAP will be severe.

Limitations of the study {#Sec11}
------------------------

Limiting this study was that its PCR panel did not include other atypical pathogens including respiratory viruses, which are common causes of lower respiratory tract infections. Furthermore, the sample was based on a pre-determined duration rather than calculating a minimum number of cases.

Conclusion and recommendations {#Sec12}
==============================

In early infancy, *Bordetella pertussis* caused a significant proportion of hospitalized CAP cases; all were ≤ 4 months old and incompletely vaccinated. This finding could emphasize the role of maternal immunization in developing countries and the importance of complying with the schedule of the DTP vaccine.
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